Business
Jefferies Downgrades Amicus to 'Buy' Amid BioMarin Acquisition, Sees Limited Upside
Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.